Back to Single Peptide Protocols
Single PeptideMetabolic & Weight Loss15 mg vialWeeklySubcutaneousGLP-1/GIP
Tirzepatide (15 mg Vial) Dosage Protocol
Tirzepatide dosage protocol for the 15 mg vial. Dual GIP/GLP-1 receptor agonist with full titration schedule and weekly injection guidance.
Vial Size
15 mg
Route
Subcutaneous
Frequency
Once weekly
Dose Range
2.5–15 mg/week
Dosage Schedule
| Period | Dose |
|---|---|
| Weeks 1–4 | 2.5 mg |
| Weeks 5–8 | 5 mg |
| Weeks 9–12 | 7.5 mg |
| Weeks 13–16 | 10 mg |
| Weeks 17–20 | 12.5 mg |
| Weeks 21+ (maintenance) | 15 mg |
Route: Subcutaneous · Frequency: Once weekly · Cycle: 16–72 weeks
How It Works
Tirzepatide is a dual GIP/GLP-1 receptor agonist (the active ingredient in Mounjaro and Zepbound). It activates both incretin receptors simultaneously, producing greater weight loss than GLP-1 agonists alone.
Potential Benefits
- •SURMOUNT-1 trial: 20.9% mean body weight loss at 72 weeks (15 mg dose).
- •Superior weight loss vs. semaglutide in SURPASS-2 trial.
- •Significant HbA1c reduction in type 2 diabetes.
- •FDA-approved for T2D (Mounjaro) and obesity (Zepbound).
Side Effects & Risks
- •Nausea, diarrhea, vomiting (most common).
- •Risk of pancreatitis (rare).
- •Contraindicated with personal/family history of MTC or MEN2.
Important Notes
- Titrate slowly — 4-week increments — to minimize GI side effects.
- FDA-approved as Mounjaro (T2D) and Zepbound (obesity).
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 28 days.
References
- [1]Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.View Source
- [2]Mounjaro (tirzepatide) Prescribing Information. Eli Lilly 2023.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.